News | December 14, 2009

APBI Reduced Recurrence in Low-Risk DCIS Patients

External Beam APBI

December 14, 2009 - Patients with low-risk ductal carcinoma in situ (DCIS) who receive accelerated partial breast irradiation (APBI) after a lumpectomy had a lower rate of local recurrence, according to new research presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ).

In DCIS, the cancer cells are inside the milk ducts of the breast, but have not spread to surrounding breast tissue. A previous study (Intergroup Study E5194) by the Eastern Cooperative Oncology Group and the North Central Cancer Treatment Group withheld radiation therapy from a low-risk subset of patients with DCIS after removal of the cancer. At five years, the local recurrence rate for low- and intermediate-grade patients was 6.8 percent, and 13.7 percent for high-grade patients.

In study, conducted by Sharad Goyal, M.D., instructor of radiation oncology at UMDNJ-Robert Wood Johnson Medical School, and senior author Bruce G. Haffty, M.D., chair of radiation oncology at CINJ and professor and chair of the department of radiation oncology at UMDNJ-Robert Wood Johnson Medical School, researchers looked at 69 patients between 2002 and 2004, who met the enrollment criteria for the previous study.

Following lumpectomy, patients in the new study were offered APBI, which is a one-week course of treatment that targets the specific area of the breast cavity where the cancer was removed. Investigators found that compared to the previous study, where radiation therapy was withheld, APBI greatly reduced the rate of local recurrence for low-risk DCIS patients (zero percent compared to 6.8 percent for low- to intermediate-grade patients and 5.3 percent compared to 13.7 percent for high-grade patients). Considering the shortened course of radiation (one week of APBI versus the traditional seven or eight), Dr. Goyal noted such treatment not only lessens the chance of recurrence but also could have great benefit to a patient’s quality of life in not having to travel continuously to the treatment site.

CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

Co-authors of the study include Frank Vicini, William Beaumont Hospital, Mich.; Peter D. Beitsch, Dallas Breast Center, Texas; Martin Keisch, Miami Brachytherapy Center, Fla.; and Maureen Lyden, M.D., Anderson Cancer Center, Texas.

For more information: www.cinj.org

Related Content

Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.
Fujifilm to Host Pediatric Imaging Best Practices Symposium at AHRA 2018
News | Pediatric Imaging | July 18, 2018
Fujifilm Medical Systems U.S.A. Inc. announced that it will offer educational opportunities and exhibit its latest...
SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Invision Diagnostics Installs VolparaEnterprise Software to Enhance Mammography Image Quality
News | Mammography | July 11, 2018
Invision Diagnostics, a provider of mobile mammography services across North and South Carolina, announced that it is...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Overlay Init